Centro Hospitalar Universitário Lisboa Central E.P.E.
- Address
- lock Available on a paid plan
Immune System Diseases Research
The Intensive Care Unit at Centro Hospitalar Universitário Lisboa Central is conducting studies that target disorders of the immune system, especially in patients receiving kidney transplants and those with severe viral infections. Trials aim to improve graft outcomes and lower mortality by testing innovative immunomodulatory therapies.
- Evaluation of ARGX-117 for delayed graft function
- Assessment of baricitinib in immunocompromised COVID-19 patients
- Investigation of strategies to prevent organ rejection in critical care
These investigations reinforce the hospital’s dedication to advancing care for immune‑related conditions and enhancing survival rates in the ICU setting.
Virus Diseases Research
Research in the ICU concentrates on emerging and pandemic viral illnesses, including Monkeypox and COVID‑19. The studies compare clinical outcomes with and without antiviral treatment, seeking to refine therapeutic guidelines for hospitalized patients.
- Cohort analysis of Monkeypox clinical outcomes
- Adaptive platform trial evaluating therapies for moderate COVID‑19
- Study of interventions to reduce mortality in severe COVID‑19 cases
By joining international collaborations, the site contributes valuable data to global efforts against viral threats and helps shape future treatment standards.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centro Hospitalar Universitário Lisboa Central E.P.E.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Cohort study of human mpox virus disease | University Of Oxford | Phase III | Not Recruiting | Aug 2022 | Jan 2024 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baricitinib | 1 | Unknown | 2021-06-03 | 2021-06-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.